These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 20873955)

  • 1. Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer.
    Ramsey SD; McCune JS; Blough DK; McDermott CL; Clarke L; Malin JL; Sullivan SD
    Am J Manag Care; 2010 Sep; 16(9):678-86. PubMed ID: 20873955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.
    Lyman GH; Dale DC; Crawford J
    J Clin Oncol; 2003 Dec; 21(24):4524-31. PubMed ID: 14673039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health care use and primary prophylaxis with colony-stimulating factors.
    Sullivan SD; Ramsey SD; Blough DK; McDermott CL; Clarke L; McCune JS
    Value Health; 2011; 14(2):247-52. PubMed ID: 21402293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of primary prophylaxis on febrile neutropenia within community practices in the US.
    Hershman D; Hurley D; Wong M; Morrison VA; Malin JL
    J Med Econ; 2009 Sep; 12(3):203-10. PubMed ID: 19723018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors.
    Minisini A; Spazzapan S; Crivellari D; Aapro M; Biganzoli L
    Crit Rev Oncol Hematol; 2005 Feb; 53(2):125-31. PubMed ID: 15661563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Policy versus practice: comparison of prescribing therapy and durable medical equipment in medical and educational settings.
    Sneed RC; May WL; Stencel C
    Pediatrics; 2004 Nov; 114(5):e612-25. PubMed ID: 15520092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis.
    Peters BG; Adkins DR; Harrison BR; Velasquez WS; Dunphy FR; Petruska PJ; Bowers CE; Niemeyer R; McIntyre W; Vrahnos D; Auberry SE; Spitzer G
    Bone Marrow Transplant; 1996 Jul; 18(1):93-102. PubMed ID: 8832001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insurance status and the use of guideline therapy in the treatment of selected cancers.
    Harlan LC; Greene AL; Clegg LX; Mooney M; Stevens JL; Brown ML
    J Clin Oncol; 2005 Dec; 23(36):9079-88. PubMed ID: 16301598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of recombinant human granulocyte colony stimulating factor (rhG-CSF) in patients receiving chemotherapy--phase I study].
    Fukutani H; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nagamine D; Shinagawa K; Tabata M; Hirano A; Mizunuma N
    Gan To Kagaku Ryoho; 1989 May; 16(5):2005-12. PubMed ID: 2471461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns for stage III colon cancer and factors related to receipt of postoperative chemotherapy in Louisiana.
    Wu X; Chen VW; Andrews PA; Chen L; Hsieh M; Fontham ET
    J La State Med Soc; 2004; 156(5):255-61. PubMed ID: 15554095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence exerted on drug prescribing by patients' attitudes and expectations and by doctors' perception of such expectations: a cohort and nested case-control study.
    Lado E; Vacariza M; Fernández-González C; Gestal-Otero JJ; Figueiras A
    J Eval Clin Pract; 2008 Jun; 14(3):453-9. PubMed ID: 18373568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of the prescribing of potentially inappropriate medications at ambulatory care visits by elderly patients covered by the Taiwanese National Health Insurance program.
    Lai HY; Hwang SJ; Chen YC; Chen TJ; Lin MH; Chen LK
    Clin Ther; 2009 Aug; 31(8):1859-70. PubMed ID: 19808145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
    Hsiao FY; Tsai YW; Huang WF
    Clin Ther; 2009 Nov; 31(11):2618-27. PubMed ID: 20110006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population variations in the initial treatment of non-small-cell lung cancer.
    Potosky AL; Saxman S; Wallace RB; Lynch CF
    J Clin Oncol; 2004 Aug; 22(16):3261-8. PubMed ID: 15310770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment patterns in patients with advanced breast cancer who were exposed to an anthracycline, a taxane, and capecitabine: a descriptive report.
    Donato BM; Burns L; Willey V; Cohenuram M; Oliveria S; Yood MU
    Clin Ther; 2010 Mar; 32(3):546-54. PubMed ID: 20399992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical studies with granulocyte colony stimulating factor (G-CSF) in patients receiving cytotoxic chemotherapy.
    Morstyn G; Campbell L; Dührsen U; Souza LM; Alton NK; Villeval JL; Nicola NA; Boyd AW; Kannourakis G; Cebon J
    Behring Inst Mitt; 1988 Aug; (83):234-9. PubMed ID: 2467651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
    von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
    Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.